---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-000424"
form_type: "8-K/A"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:56:06.422916+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences appoints Dayno as Interim President and CEO; details compensation

## Summary
- Dr. Jeffrey Dayno appointed Interim President and CEO effective Jan 6, 2023; continues as CMO.
- Annual base salary set at $530,000; target annual bonus of 75% of base salary.
- One-time cash bonus of $300,000 payable upon earlier of June 30, 2024 or change in control.
- Upon permanent CEO appointment, Dayno reverts to EVP/CMO with base salary $530,000 and 75% target bonus.
- Executive Chairman Jeffrey Aronin to receive $500,000 annual cash payment, pro-rated quarterly.

## SEC filing metadata
- accession: 0001558370-23-000424
- form_type: 8-K/A
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/0001558370-23-000424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/hrmy-20230105x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-000424
- JSON: https://secwatch.observer/filing/0001558370-23-000424.json
- Plain text: https://secwatch.observer/filing/0001558370-23-000424.txt

## Key facts
- Executive change
  Jeffrey S. Aronin was appointed as Executive Chairman at Harmony Biosciences Holdings, Inc..
  - Action: appointed
  - Role: Executive Chairman
  source text: the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/0001558370-23-000424-index.htm
- Executive change
  John Jacobs resigned as other at Harmony Biosciences Holdings, Inc..
  - Action: resigned
  source text: in connection with Mr. John Jacobs’ resignation from the Company and the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/0001558370-23-000424-index.htm
- Executive change
  Jeffrey M. Dayno was appointed as Interim President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..
  - Action: appointed
  - Role: Interim President and Chief Executive Officer
  source text: the Board appointed Dr. Jeffrey M. Dayno as the Company’s Interim President and Chief Executive Officer (“CEO”), effective January 6, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/0001558370-23-000424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.